Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00499018
Status:
UNKNOWN
Last Update Posted:
2011-02-15
First Post:
2007-07-10
Brief Title:
Dose Dense Chemotherapy Rituximab -Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Fondazione Italiana Linfomi - ETS
Study Overview
Official Title:
A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk IPI 2-3 Diffuse Large B-Cell Lymphoma Dose Dense Chemotherapy Rituximab - Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells
Status:
UNKNOWN
Status Verified Date:
2011-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DLCL04
Brief Summary:
The purpose of this study is to define an improvement in patients randomized in four different arms
Arm 1 R-MegaCHOP14x4 R-MAD MAD BEAM ASCT Arm 1BIS R-CHOP14x4 R-MAD MAD BEAM ASCT Arm 2 R-MegaCHOP14x4 R-MegaCHOP14x2 Arm 2BIS R-CHOP14x4 R-CHOP14x4 Which are different in dose dense chemotherapy Rituximab with or without intensified high dose chemoimmunotherapy and support of peripheral autologous stem cells
Arm 1 R-MegaCHOP14x4 R-MAD MAD BEAM ASCT Arm 1BIS R-CHOP14x4 R-MAD MAD BEAM ASCT Arm 2 R-MegaCHOP14x4 R-MegaCHOP14x2 Arm 2BIS R-CHOP14x4 R-CHOP14x4 Which are different in dose dense chemotherapy Rituximab with or without intensified high dose chemoimmunotherapy and support of peripheral autologous stem cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT number 2007-000275-42 | None | None | None |